D
인투셀
287840KOSDAQ자연과학 및 공학 연구개발업34.0 / 100
Reference Date: 2026-06-10
Financial Score7.5 / 40
News Sentiment12.5 / 25
Momentum4.0 / 20
Disclosure10.0 / 15
AI Analysis: the high debt ratio poses financial risk, PBR raises overvaluation concerns. Plunged 30.2% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
IntuCell is an ADC platform technology company specializing in linker and drug development, leveraging its OHPAS linker and PMT platform technologies to enhance drug delivery efficiency and selectivity. The company utilizes proprietary drug technologies such as Duocarmycin and Nexatecan to establish a competitive edge in oncology, with a pipeline including the B7-H3-targeting ADC candidate ITC-6146RO.
Number of Employees
—
Average Salary
—
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 62.704.0Point
PBR
14.69Industry Average 3.240.0Point
4.5x industry avg (risky)
ROE
-65.72Industry Average -32.093.5Point
2.0x industry avg (excellent)
Debt Ratio
53.66Industry Average 7.310.0Point
7.3x industry avg (risky)
Trend 2024~20250.0 / 10 points
Revenue Growth Rate
0.0 / 3
Avg ▼20.9% (1-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼5.2% (1-year basis)
ROE Trend
0.0 / 4
Avg ROE -80.6% (improving, 2yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (2%, downtrend)
Current 24,200Won52-week high 71,00052-week low 22,800
1-month return0.0Point
1m -30.16% (strong drop)
Volume trend3.0Point
Volume flat
Detailed Disclosure
3 totalPositive 0Neutral 3Negative 0
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-05
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-05
- Neutral분기보고서 (2026.03)2026-05-15